|
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech Sanofi-Synthelabo Eli Lilly and Company |
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00142467 |
The purpose of this study is to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good or bad) it has on patients with hepatocellular carcinoma.
Condition | Intervention | Phase |
Hepatocellular Carcinoma |
Drug: Gemcitabine Drug: Oxaliplatin Drug: Bevacizumab |
Phase II |
MedlinePlus related topics: | Cancer Liver Cancer |
ChemIDplus related topics: | Gemcitabine hydrochloride Gemcitabine Bevacizumab Oxaliplatin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Patients With Hepatocellular Carcinoma |
Estimated Enrollment: | 30 |
Study Start Date: | April 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Massachusetts General Hospital | |||||
Boston, Massachusetts, United States, 02114 | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
Beth Israel Deaconess Medical Center | |||||
Boston, Massachusetts, United States, 02115 |
Massachusetts General Hospital |
Dana-Farber Cancer Institute |
Beth Israel Deaconess Medical Center |
Brigham and Women's Hospital |
Genentech |
Sanofi-Synthelabo |
Eli Lilly and Company |
Principal Investigator: | Andrew Zhu, MD | Massachusetts General Hospital |
Study ID Numbers: | 03-390 |
First Received: | August 31, 2005 |
Last Updated: | August 31, 2005 |
ClinicalTrials.gov Identifier: | NCT00142467 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|